Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease

Isabelle Amigues,1 Deepa Ramadurai,2 Jeffrey J Swigris3 1Division of Rheumatology, National Jewish Health, Denver, CO, USA; 2Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 3Division of Pulmonary, Critical Care and Sleep Medicine, Interstitial Lung Disease Pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amigues I, Ramadurai D, Swigris JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	rheumatoid arthritis interstitial lung disease pulmonary fibrosis usual interstitial pneumonia biomarker antibody Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/024da8104be142a3b5f758274df2aa7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:024da8104be142a3b5f758274df2aa7f
record_format	dspace
spelling	oai:doaj.org-article:024da8104be142a3b5f758274df2aa7f2021-12-02T07:59:31ZCurrent Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease1179-156Xhttps://doaj.org/article/024da8104be142a3b5f758274df2aa7f2019-10-01T00:00:00Zhttps://www.dovepress.com/current-perspectives-on-emerging-biomarkers-for-rheumatoid-arthritis-a-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XIsabelle Amigues,1 Deepa Ramadurai,2 Jeffrey J Swigris3 1Division of Rheumatology, National Jewish Health, Denver, CO, USA; 2Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 3Division of Pulmonary, Critical Care and Sleep Medicine, Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USACorrespondence: Jeffrey J SwigrisNational Jewish Health, 1400 Jackson Street, Denver, CO 80206, USAEmail swigrisj@njc.orgAbstract: Rheumatoid arthritis (RA) is a common systemic autoimmune disease whose fibro-inflammatory manifestations may affect a number of tissues and organs, including the lungs. In fact, interstitial lung disease (ILD) is a leading cause of mortality among patients with RA. RA-related interstitial lung disease (RA-ILD) most often presents in an injury pattern called usual interstitial pneumonia (UIP), which portends a relatively worse prognosis than other less commonly occurring patterns of RA-ILD, like non-specific interstitial pneumonia (NSIP). Biomarkers from serum or bronchoalveolar lavage fluid could aid in the identification of patients at risk for RA-ILD, the detection of patients most likely to develop the UIP pattern of RA-ILD, and the prediction of disease behaviour over time. Notably, the use of highly sensitive serologic biomarkers, including rheumatoid factor (RF) and antibodies targeting cyclic citrullinated peptides, while somewhat specific for RA joint disease, have only limited utility as biomarkers for RA-ILD. Candidate biomarkers for RA-ILD include these and other autoantibodies as well as certain genes and molecules that hold promise as biomarkers in other forms of ILD. In this manuscript, we summarize the state of knowledge on biomarkers for the development and progression of RA-ILD.Keywords: rheumatoid arthritis, interstitial lung disease, pulmonary fibrosis, usual interstitial pneumonia, biomarker, antibodyAmigues IRamadurai DSwigris JJDove Medical Pressarticlerheumatoid arthritisinterstitial lung diseasepulmonary fibrosisusual interstitial pneumoniabiomarkerantibodyDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 11, Pp 229-235 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis interstitial lung disease pulmonary fibrosis usual interstitial pneumonia biomarker antibody Diseases of the musculoskeletal system RC925-935
spellingShingle	rheumatoid arthritis interstitial lung disease pulmonary fibrosis usual interstitial pneumonia biomarker antibody Diseases of the musculoskeletal system RC925-935 Amigues I Ramadurai D Swigris JJ Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
description	Isabelle Amigues,1 Deepa Ramadurai,2 Jeffrey J Swigris3 1Division of Rheumatology, National Jewish Health, Denver, CO, USA; 2Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 3Division of Pulmonary, Critical Care and Sleep Medicine, Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USACorrespondence: Jeffrey J SwigrisNational Jewish Health, 1400 Jackson Street, Denver, CO 80206, USAEmail swigrisj@njc.orgAbstract: Rheumatoid arthritis (RA) is a common systemic autoimmune disease whose fibro-inflammatory manifestations may affect a number of tissues and organs, including the lungs. In fact, interstitial lung disease (ILD) is a leading cause of mortality among patients with RA. RA-related interstitial lung disease (RA-ILD) most often presents in an injury pattern called usual interstitial pneumonia (UIP), which portends a relatively worse prognosis than other less commonly occurring patterns of RA-ILD, like non-specific interstitial pneumonia (NSIP). Biomarkers from serum or bronchoalveolar lavage fluid could aid in the identification of patients at risk for RA-ILD, the detection of patients most likely to develop the UIP pattern of RA-ILD, and the prediction of disease behaviour over time. Notably, the use of highly sensitive serologic biomarkers, including rheumatoid factor (RF) and antibodies targeting cyclic citrullinated peptides, while somewhat specific for RA joint disease, have only limited utility as biomarkers for RA-ILD. Candidate biomarkers for RA-ILD include these and other autoantibodies as well as certain genes and molecules that hold promise as biomarkers in other forms of ILD. In this manuscript, we summarize the state of knowledge on biomarkers for the development and progression of RA-ILD.Keywords: rheumatoid arthritis, interstitial lung disease, pulmonary fibrosis, usual interstitial pneumonia, biomarker, antibody
format	article
author	Amigues I Ramadurai D Swigris JJ
author_facet	Amigues I Ramadurai D Swigris JJ
author_sort	Amigues I
title	Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_short	Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_full	Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_fullStr	Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_full_unstemmed	Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
title_sort	current perspectives on emerging biomarkers for rheumatoid arthritis-associated interstitial lung disease
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/024da8104be142a3b5f758274df2aa7f
work_keys_str_mv	AT amiguesi currentperspectivesonemergingbiomarkersforrheumatoidarthritisassociatedinterstitiallungdisease AT ramaduraid currentperspectivesonemergingbiomarkersforrheumatoidarthritisassociatedinterstitiallungdisease AT swigrisjj currentperspectivesonemergingbiomarkersforrheumatoidarthritisassociatedinterstitiallungdisease
_version_	1718398703346122752

Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease

Ejemplares similares